Many randomized trials in cardiovascular disease have repeat nonfatal events (such as
hospitalizations) occurring during patient follow-up; yet, it remains common practice to have …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …

Conclusion Given rapid evolution of natural history in ATTR amyloidosis, the utility of
historical control data is limited. Leveraging contemporary real-world data is essential for …

Background The primary end point in most heart failure (HF) trials is a composite of time to a
first worsening HF event or cardiovascular death. Prevention of recurrent events and …

Background Treatment of patients with recurrence of in-stent restenosis (ISR) remains
particularly challenging, with data and guideline recommendations for repeat percutaneous …

Background The sodium glucose cotransporter‐2 inhibitors are guideline‐recommended to
treat heart failure across the spectrum of left ventricular ejection fraction; however, economic …

Abstract Introduction: Peritoneal Ultrafiltration (PUF) has been proposed as an additional
therapeutic option for Refractory Congestive Heart Failure (RCHF) patients. Despite …

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Therapeutic
agents, such as those that lower low-density lipoprotein cholesterol, have been a critical …

In randomised controlled trials, the outcome of interest could be recurrent events, such as
hospitalisations for heart failure. If mortality rates are non‐negligible, both recurrent events …

Composite time-to-event endpoints are commonly used in cardiovascular outcome trials. For
example, the IMPROVE-IT trial comparing ezetimibe+ simvastatin to placebo+ simvastatin in …